American Medical Systems' US prostate trial begins, Euro launch ahead:
This article was originally published in Clinica
American Medical Systems (AMS) has begun a phase I/II US trial of it AMS ProstaJect ethanol injection system for treating benign prostate hyperplasia (see Clinica No 942, p 22). The Minneapolis, Minnesota company expects to enrol patients from 13 US centres across the US. The transurethral device uses ethanol to ablate the cells of an enlarged prostate gland. AMS will launch the device in Europe this month.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.